PEPG
$5.09
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-co...
Recent News
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA
The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
The mean of analysts' price targets for PepGen (PEPG) points to a 75.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
PepGen Inc.'s (NASDAQ:PEPG) largest shareholders are individual investors with 39% ownership, private equity firms own 36%
Key Insights PepGen's significant individual investors ownership suggests that the key decisions are influenced by...
BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform Rating
PepGen Inc. (NASDAQ:PEPG) is one of the hot stocks to buy with huge upside potential. On October 9, BofA raised the firm’s price target on PepGen to $3 from $1 and maintained an Underperform rating on the shares. This sentiment came out as the firm updated its financial model to assign a standalone value to […]